Data / Research funding / Texas / Fannin Partners, LLC
Fannin Partners, LLC: 6 NIH awards ($5.1M), fiscal years 2021 to 2026
Fannin Partners, LLC in Houston, TX is funded under 6 NIH awards ($5.1M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DAHAYJEBV8K1
- State
- Texas
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,084,309 | April 1, 2022 | August 31, 2026 | VARADHACHARY, ATUL | reporter.nih.gov |
| Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $1,972,317 | July 1, 2021 | June 30, 2024 | VEGA, STEPHANIE PRISCILLA | reporter.nih.gov |
| Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder | NIH | National Institute on Drug Abuse | 2024 | $320,000 | May 1, 2024 | April 30, 2026 | VARADHACHARY, ATUL | reporter.nih.gov |
| Developing Scg3 Raptamers as a novel targeted therapy for wet AMD | NIH | National Eye Institute | 2025 | $300,016 | September 1, 2025 | August 31, 2026 | VARADHACHARY, ATUL | reporter.nih.gov |
| Expediting the Biomarker Discovery Process Through a Novel Bead-Based Aptamer Capture Platform | NIH | National Institute of General Medical Sciences | 2022 | $299,921 | August 15, 2022 | August 14, 2024 | VEGA, STEPHANIE PRISCILLA | reporter.nih.gov |
| Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $139,727 | March 1, 2021 | July 31, 2023 | HEFFERNAN, MICHAEL JOHN | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 2 | $1,300,013 | 0 | $0 |
| 2024 | 1 | $320,000 | 0 | $0 |
| 2023 | 1 | $84,315 | 0 | $0 |
| 2022 | 3 | $2,278,261 | 0 | $0 |
| 2021 | 2 | $1,133,701 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.395 | November 2, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| Autism Centers of Excellence R01 | RFA-HD-27-001 | NIH | 93.865 | November 2, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| Autism Centers of Excellence P50 | RFA-HD-27-002 | NIH | 93.865 | November 2, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional) | RFA-OD-27-009 | NIH | 93.859 | November 10, 2026 | Not listed | Same assistance listing 93.859 as 1 award here |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) | PAR-26-152 | NIH | 93.395 | November 11, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | PAR-24-089 | NIH | 93.279 | November 13, 2026 | $750,000 | Same assistance listing 93.279 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.865 | November 16, 2026 | $50,000 | Same assistance listing 93.865 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.865 | November 18, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.865 | November 18, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.395 | November 20, 2026 | Not listed | Same assistance listing 93.395 as 1 award here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.865 | November 23, 2026 | $375,000 | Same assistance listing 93.865 as 1 award here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.865 | November 24, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.279 | December 3, 2026 | Not listed | Same assistance listing 93.279 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.279 | December 3, 2026 | Not listed | Same assistance listing 93.279 as 1 award here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.865 | December 4, 2026 | Not listed | Same assistance listing 93.865 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.865 | January 5, 2027 | Not listed | Same assistance listing 93.865 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.865 | January 5, 2027 | Not listed | Same assistance listing 93.865 as 1 award here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.865 | January 7, 2027 | $375,000 | Same assistance listing 93.865 as 1 award here |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | PAR-25-079 | NIH | 93.395 | January 7, 2027 | $500,000 | Same assistance listing 93.395 as 1 award here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.395 | January 7, 2027 | $499,999 | Same assistance listing 93.395 as 1 award here |
Topics of its NIH awards
- Biotechnology
- Neurosciences
- Pediatric
- Prevention
- Perinatal Period - Conditions Originating in Perinatal Period
- Preterm, Low Birth Weight and Health of the Newborn
- Rare Diseases
- Translational Research
- Emergency Care
- Immunization
- Physical Injury - Accidents and Adverse Effects
- Bioengineering
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.